Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

BEVERLY, Mass.–(BUSINESS WIRE)– #Fcfusion–Akston Biosciences announced positive results from a Phase I trial of AKS-452, its protein subunit, COVID-19 vaccine candidate.
Click here to view original post